-
Mavorixafor in WHIM Syndrome: Phase 3 Evidence
2026-09-01
The reference commentary examines a placebo-controlled phase 3 trial showing that oral CXCR4 antagonism with mavorixafor prolonged neutrophil and lymphocyte availability and reduced infections in patients with WHIM syndrome. Its importance lies in targeting the disease-driving trafficking defect with a practical oral regimen, while leaving longer-term questions about immune normalization, malignancy risk, and lifelong safety unresolved.
-
RSL3, PARP1, and Ferroptosis–Apoptosis Crosstalk
2026-09-01
A 2025 study shows that RSL3 connects ferroptosis with apoptosis through two distinct PARP1-regulatory routes: caspase-dependent cleavage and depletion of full-length PARP1 through altered m6A-dependent translation. The findings provide a mechanistic framework for interpreting RSL3 responses in PARP inhibitor-resistant cancer models and for designing assays that distinguish apoptotic execution from ferroptotic stress.
-
DDI2–NFE2L1 Protects Cells from Ferroptosis
2026-08-31
Ofoghi and colleagues show that ferroptosis triggers proteasome impairment and global hyperubiquitylation, while DDI2-dependent activation of NFE2L1 restores proteasome capacity and improves cell survival. The study identifies the DDI2–NFE2L1–ubiquitin-proteasome axis as a mechanistically supported point for sensitizing cells to ferroptosis, including through the clinical drug nelfinavir.
-
Fucoidan and the Gut–Liver Axis in Chemotherapy Injury
2026-08-31
A 2026 study identifies intestinal barrier failure and neutrophil extracellular traps as linked drivers of irinotecan-induced steatohepatitis. Its findings suggest that Fucoidan may protect the liver indirectly by preserving gut integrity, limiting lipopolysaccharide translocation, and suppressing excessive NET-associated inflammation.
-
α-Bungarotoxin in Translational Cholinergic Research
2026-08-30
α-Bungarotoxin is more than a receptor antagonist: it is a causal probe for testing how α7 nicotinic acetylcholine receptor signaling shapes inflammation, cell death, and tissue function. This article connects nicotinic receptor blockade with recent placental necroptosis findings and offers a practical framework for translational study design.
-
Octyl-α-ketoglutarate for HIF-1α Studies
2026-08-29
Octyl-α-ketoglutarate is a cell-permeable prolyl hydroxylase substrate for testing whether α-ketoglutarate availability changes HIF-1α turnover in metabolically rewired cells. This practical guide converts IDH and TCA-cycle hypotheses into controlled dosing, hypoxia comparisons, and orthogonal readouts, with troubleshooting for solvent, timing, and interpretation.
-
Nelfinavir Mesylate: Virology to Ferroptosis
2026-08-28
Nelfinavir Mesylate is a high-value HIV-1 protease inhibitor for antiviral assays and a mechanistic probe for DDI2–NFE2L1 control of ferroptosis. This workflow-focused guide shows how to separate HIV replication suppression from proteostasis and cell-death effects while improving solubility, controls, and assay interpretation.
-
Ibrexafungerp Against Resistant Candida auris
2026-08-28
Wiederhold and colleagues show that ibrexafungerp retained in vitro activity against fluconazole-resistant Candida auris and improved outcomes in a neutropenic mouse model even when therapy began after infection was established. The study is important because it connects resistance-aware susceptibility testing with an oral glucan-synthesis inhibitor and delayed-treatment efficacy, while providing a useful benchmark for interpreting cell-wall-active antifungal agents.
-
(R)-MG132: A Rigorous Control for Cancer Metabolism
2026-08-27
(R)-MG132 is a functionally inactive MG-132 enantiomer designed to strengthen proteasome inhibition validation. This article shows how it can clarify whether metabolic and post-transcriptional phenotypes, including the HNRNPU–PHGDH axis, are genuinely proteasome-dependent or arise from confounding effects.
-
Hexetidine (NSC-17764): Translational Strategy
2026-08-27
Hexetidine (NSC-17764) offers translational researchers a practical model for studying broad-spectrum oral antimicrobial activity without reducing performance to a single MIC value. This article connects membrane-level biology, adsorption and washout effects, biofilm assay design, and clinical-use considerations to support more predictive oral infection workflows.
-
T7 RNA Polymerase for Precise RNA Synthesis
2026-08-26
T7 RNA Polymerase is a recombinant enzyme expressed in E. coli that selectively transcribes RNA from DNA templates carrying a T7 promoter. Its defined template requirements support in vitro transcription, RNA vaccine production, antisense RNA and RNAi research, and RNA structure-function studies.
-
(-)-Arctigenin MEK1 Inhibitor Workflows
2026-08-26
(-)-Arctigenin provides a chemically controlled way to interrogate LPS–NF-κB–iNOS signaling alongside MEK1 biology. This guide translates macrophage extracellular-vesicle findings in breast cancer into practical treatment, co-culture, invasion, and pathway-validation workflows.
-
Atorvastatin as a Ferroptosis Research Probe
2026-08-25
Atorvastatin is more than an HMG-CoA reductase inhibitor: it is a practical probe for connecting mevalonate biology, ferroptosis, and disease-specific phenotypes. This guide translates recent hepatocellular carcinoma findings into rigorous assay and interpretation decisions.
-
Myriocin Workflows for Sphingolipid Research
2026-08-25
Myriocin provides a direct pharmacological route to suppress serine palmitoyltransferase and interrogate de novo sphingolipid synthesis. This workflow-focused guide connects lipid measurements with SPTLC2 biology, cardiac remodeling models, cancer research, and cell cycle regulation while emphasizing controls, dosing logic, and troubleshooting.
-
BET Inhibition in HPV-16-Associated HNSCC
2026-08-24
The reference preprint examines how BET protein inhibition affects viral and cellular transcription in HPV-16-associated head and neck squamous cell carcinoma. Its central finding is that responses are heterogeneous across models: BET inhibition consistently suppresses key viral and growth-related programs in some contexts, but E6 loss does not uniformly restore p53 signaling or produce the same downstream phenotype.